M&A Deal Summary

bioMerieux Acquires Invisible Sentinel

On February 7, 2019, bioMerieux acquired medical products company Invisible Sentinel for 75M USD

Acquisition Highlights
  • This is bioMerieux’s 8th transaction in the Medical Products sector.
  • This is bioMerieux’s 3rd largest (disclosed) transaction.
  • This is bioMerieux’s 7th transaction in the United States.
  • This is bioMerieux’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2019-02-07
Target Invisible Sentinel
Sector Medical Products
Buyer(s) bioMerieux
Deal Type Add-on Acquisition
Deal Value 75M USD

Target

Invisible Sentinel

Philadelphia, Pennsylvania, United States
Invisible Sentinel, Inc. develops, manufactures and markets innovative and user-friendly molecular diagnostic tools for the rapid, accurate and reliable detection of pathogens and spoilage organisms in food and beverage.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

bioMerieux

Marcy l'Etoile, France
Category Company
Founded 1963
Sector Life Science
Employees13,409
Revenue 3.7B EUR (2023)
DESCRIPTION

bioMerieux is a provider in the field of in vitro diagnostics. bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. bioMerieux was founded in 1963 and is based in Marcy l'Etoile, France.

DEAL STATS #
Overall 20 of 21
Sector (Medical Products) 8 of 9
Type (Add-on Acquisition) 16 of 17
State (Pennsylvania) 1 of 1
Country (United States) 7 of 8
Year (2019) 1 of 1
Size (of disclosed) 3 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-11-09 Suzhou Hybiome Biomedical Engineering

Suzhou, China

Suzhou Hybiome Biomedical Engineering Co.Ltd. is specialized in automated immunoassay tests. The company develops, manufactures and markets a complete range of diagnostic solutions (reagents, instruments, and software) cleared by the China Food and Drug Administration (CFDA). Hybiome markets two automated, mid-throughput immunoassay systems (AE-180 and AE-240) using the latest generation CLIA1 technology and featuring a menu of nearly 80 parameters. Hybiome also recently received CFDA clearance for the AE-120 system, to further increase access to its menu of assays. Hybiome’s installed base has about 1,000 active instruments that are used primarily in medium-sized hospitals (100 to 500 beds), known as Grade 2 facilities.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-12 Specific Diagnostics

San Jose, California, United States

Specific Diagnostics is a developer of in vitro diagnostic systems for the detection and identification of microorganisms while they grow in culture. Specific Diagnostics was founded in 2011 and is based in San Jose, California.

Buy -
Mergr

Product

Company

Legal